Volume 31, Number 8—August 2025
Dispatch
Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016–2023
Anna D. Baker
, Jeremy A.W. Gold, Kaitlin Forsberg, Sophie Jones, and Meghan M. Lyman
, Jeremy A.W. Gold, Kaitlin Forsberg, Sophie Jones, and Meghan M. Lyman
Table 1
Characteristics of patients with Candida auris screening cases with and without progression to clinical case status, United States, 2016–2023*
| Characteristic | All, N = 21,195 | With clinical case, n = 1,458 | Without clinical case, n = 19,737 | p value† |
|---|---|---|---|---|
| Median age at collection of screening case specimen, y (IQR), n = 17,928 |
68 (58–76) |
67 (59–76) |
68 (58–77) |
0.650 |
| Age group at collection of screening case specimen, y, n = 17,928 | 0.113 | |||
| <45 | 1,738 | 118 (6.8) | 1,620 (93.2) | |
| 45–54 | 1,778 | 105 (5.9) | 1,673 (94.1) | |
| 55–64 | 3,725 | 279 (7.5) | 3,446 (92.5) | |
| 65–74 | 5,239 | 368 (7.0) | 4,871 (93.0) | |
| 75–84 | 3,808 | 274 (7.2) | 3,534 (92.8) | |
| >85 |
1,640 |
94 (5.7) |
1,546 (94.3) |
|
| Sex, n = 16,446 | 0.478 | |||
| M | 9,448 | 668 (7.1) | 8,780 (92.9) | |
| F |
6,998 |
515 (7.4) |
6,483 (92.6) |
|
| Antimicrobial Resistance Laboratory Network region of the facility of collection for screening case specimen‡ | <0.001 | |||
| West | 6,617 | 898 (13.6) | 5,719 (86.4) | |
| Midwest | 4,264 | 96 (2.3) | 4,168 (97.7) | |
| Southeast | 4,235 | 56 (1.3) | 4,179 (98.7) | |
| Northeast | 3,570 | 302 (8.5) | 3,268 (91.5) | |
| Mid-Atlantic | 1,484 | 64 (4.3) | 1,420 (95.7) | |
| Mountain | 977 | 42 (4.3) | 935 (95.7) | |
| Central |
48 |
0 |
48 (100.0) |
|
| Facility type of screening case specimen collection, n = 17,357 | <0.001 | |||
| Long-term acute care hospital | 8,716 | 907 (10.4) | 7,809 (89.6) | |
| Acute care hospital | 5,033 | 299 (5.9) | 4,734 (94.1) | |
| Ventilator-equipped skilled nursing facility | 2,912 | 150 (5.2) | 2,762 (94.8) | |
| Skilled nursing facility | 490 | 13 (2.7) | 477 (97.3) | |
| Other¶ | 206 | 4 (1.9) | 202 (98.1) | |
*Values are no. (%) except as indicated. †p values were calculated using χ2 tests to compare characteristics of patients with a C. auris screening case who had (vs. did not have) progression to a C. auris clinical case. ‡From https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/domestic.html. Data from 2023 were unavailable from 1 state in the Central region. ¶Includes those listed as other (n = 193), inpatient rehabilitation (n = 12), and outpatient (n = 1).
Page created: June 16, 2025
Page updated: July 22, 2025
Page reviewed: July 22, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.